注册 | 登录
点击这里给我发消息
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   基因重组   >   Anti-TLR4 Reference Antibody (Paridiprubart)   

Anti-TLR4 Reference Antibody (Paridiprubart)

Recombinant Antibody

     
  • 0 - Anti-TLR4 Reference Antibody (Paridiprubart) APR10584
    Anti-TLR4 Reference Antibody (Paridiprubart) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
  • 0 - Anti-TLR4 Reference Antibody (Paridiprubart) APR10584
    The purity of Anti-TLR4 Reference Antibody (Paridiprubart) is 98%, determined by SEC-HPLC.
  • 0 - Anti-TLR4 Reference Antibody (Paridiprubart) APR10584
    PLVX-puro-hu-TLR4-P2A-EGFP cell line were stained with Paridiprubart and negative control protein respectively, washed and then followed by PE and analyzed with FACS, with the EC50 is 0.10 µg/mL.
  • 产品详情
  • 实验流程
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession O00206
Reactivity Human
Clonality Monoclonal
Isotype IgG1
Calculated MW 95680 Da
Additional Information
Target/Specificity TLR4
Endotoxin < 0.001EU/ µg,determined by LAL method.
Conjugation Unconjugated
Expression system CHO
Format Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name TLR4
Function Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways (PubMed:10835634, PubMed:15809303, PubMed:16622205, PubMed:17292937, PubMed:17478729, PubMed:20037584, PubMed:20711192, PubMed:23880187, PubMed:27022195, PubMed:29038465, PubMed:17803912, PubMed:15852007). At the plasma membrane, cooperates with LY96 to mediate the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:27022195). Also involved in LPS- independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+) (PubMed:20711192). Mechanistically, acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:10835634, PubMed:21393102, PubMed:27022195, PubMed:36945827, PubMed:9237759). Alternatively, CD14-mediated TLR4 internalization via endocytosis is associated with the initiation of a MYD88-independent signaling via the TICAM1-TBK1-IRF3 axis leading to type I interferon production (PubMed:14517278). In addition to the secretion of proinflammatory cytokines, initiates the activation of NLRP3 inflammasome and formation of a positive feedback loop between autophagy and NF-kappa-B signaling cascade (PubMed:32894580). In complex with TLR6, promotes inflammation in monocytes/macrophages by associating with TLR6 and the receptor CD86 (PubMed:23880187). Upon ligand binding, such as oxLDL or amyloid-beta 42, the TLR4:TLR6 complex is internalized and triggers inflammatory response, leading to NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway (PubMed:23880187). In myeloid dendritic cells, vesicular stomatitis virus glycoprotein G but not LPS promotes the activation of IRF7, leading to type I IFN production in a CD14- dependent manner (PubMed:15265881, PubMed:23880187). Required for the migration-promoting effects of ZG16B/PAUF on pancreatic cancer cells.
Cellular Location Cell membrane; Single-pass type I membrane protein. Early endosome. Cell projection, ruffle {ECO:0000250|UniProtKB:Q9QUK6}. Note=Upon complex formation with CD36 and TLR6, internalized through dynamin-dependent endocytosis (PubMed:20037584). Colocalizes with RFTN1 at cell membrane and then together with RFTN1 moves to endosomes, upon lipopolysaccharide stimulation. Co-localizes with ZG16B/PAUF at the cell membrane of pancreatic cancer cells (PubMed:36232715)
Tissue Location Highly expressed in placenta, spleen and peripheral blood leukocytes (PubMed:9237759, PubMed:9435236). Detected in monocytes, macrophages, dendritic cells and several types of T-cells (PubMed:27022195, PubMed:9237759). Expressed in pancreatic cancer cells but not in normal pancreatic cells (at protein level) (PubMed:36232715).
Research Areas
FeedBack

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-88856768 tech-china@abcepta.com.


我要评价